Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
38.97
-0.52 (-1.32%)
Sep 3, 2026, 2:53 PM EDT - Market open
Immunovant Market Cap
Immunovant has a market cap or net worth of $8.05 billion as of September 3, 2026. Its market cap has increased by 206.41% in one year.
Market Cap
8.05B
Enterprise Value
7.25B
1-Year Change
206.41%
Ranking
Category
Stock Price
$38.97
ChartMarket Cap Chart
Since June 21, 2019, Immunovant's market cap has increased from $124.38M to $8.05B, an increase of 6,371.85%. That is a compound annual growth rate of 78.34%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 3, 2026 | 8.05B | 56.24% |
| Dec 31, 2025 | 5.15B | 41.70% |
| Dec 31, 2024 | 3.64B | -40.34% |
| Dec 29, 2023 | 6.09B | 165.79% |
| Dec 30, 2022 | 2.29B | 134.03% |
| Dec 31, 2021 | 979.80M | -78.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 21, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Praxis Precision Medicines | 9.98B |
| Kymera Therapeutics | 9.86B |
| Protagonist Therapeutics | 9.45B |
| Vaxcyte | 9.16B |
| Crinetics Pharmaceuticals | 9.01B |
| ImmunityBio | 8.43B |
| TG Therapeutics | 8.07B |
| Spyre Therapeutics | 7.68B |